Cargando…

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Hui, Lu, Xuechun, Wang, Xiaohui, Liu, Yang, Guo, Bo, Zhang, Yan, Zhang, Wenying, Nie, Jing, Feng, Kaichao, Chen, Meixia, Zhang, Yajing, Wang, Yao, Shi, Fengxia, Fu, Xiaobing, Zhu, Hongli, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054619/ https://www.ncbi.nlm.nih.gov/pubmed/24963497 http://dx.doi.org/10.1155/2014/371087

Ejemplares similares

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma
por: Mei, Qian, et al.
Publicado: (2015)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
por: Dai, Hanren, et al.
Publicado: (2015)

DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
por: Nie, Jing, et al.
Publicado: (2016)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports
por: LIN, JIE, et al.
Publicado: (2013)

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8(+) progenitor exhausted T cell expansion in tumor models
por: Li, Xiang, et al.
Publicado: (2023)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
por: Taib, Nassiba, et al.
Publicado: (2023)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
por: Jonas, Brian A., et al.
Publicado: (2023)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia
por: Han, Panpan, et al.
Publicado: (2021)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment
por: Yu, Ganjun, et al.
Publicado: (2018)

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
por: Yu, Ganjun, et al.
Publicado: (2022)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report
por: Ding, Xiao-Sheng, et al.
Publicado: (2021)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
por: Wang, Jing, et al.
Publicado: (2022)

A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
por: Zhou, Menglong, et al.
Publicado: (2022)

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ(+) CD4(+) T Cells Through Enhancing IκBα Degradation and NF-κB Activation
por: Li, Xiang, et al.
Publicado: (2021)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report
por: Li, Lin-Jie, et al.
Publicado: (2022)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism
por: Gutierrez, Wade R., et al.
Publicado: (2022)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia
por: Han, Panpan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7l3dr8n3go9iti5puli9ccvhdj